Background
Abnormal tau accumulation within the brain plays an important role in tauopathies such as Alzheimer’s disease and Frontotemporal dementia. High-resolution imaging of tau deposits at the whole-brain scale in animal disease models are highly desired. Herein, we approach this challenge by non-invasively imaging the brain of P301L mice of 4-repeat tau with concurrent volumetric multi-spectral optoacoustic tomography (vMSOT) at ~ 115 µm spatial resolution using tau-targeted pyridinyl-butadienyl-benzothiazole derivative PBB5 (i.v.).
Results
PBB5 showed specific binding to recombinant K18 tau fibrils by fluorescence assay, to post-mortem Alzheimer’s disease brain tissue homogenate by competitive binding against [11C]PBB3, and to tau deposits (AT-8 positive) in post-mortem corticobasal degeneration and progressive supranuclear palsy brains. Concurrent vMSOT and epi-fluorescence imaging of in vivo PBB5 targeting (i.v.) was performed in P301L and non-transgenic littermate mice. A dose dependent optoacoustic and fluorescence signal intensity was observed in the mouse brains with i.v. administration of different concentrations of PBB5. i.v. administration of PBB5 in P301L mice showed higher retention in tau-laden cortex and hippocampus compared to wild-type, confirmed by ex vivo vMSOT, epi-fluorescence, multiphoton microscopy, immunofluorescence staining using AT-8 antibody for phosphorylated tau.
Conclusions
We demonstrated non-invasive 3D whole-brain imaging of tau in P301L mice with a vMSOT system using PBB5 at a previously unachieved ~ 115 µm spatial resolution. This platform provides new tool to study tau spreading and clearance in tauopathy mouse model, foreseeable in monitoring of tau targeting putative therapeutics.